Classical Hodgkin Lymphoma · line 1 · N+AVD (Nivolumab + Adriamycin + Vinblastine + Dacarbazine), 6 cycles — emerging 1L standard advanced cHL (SWOG S1826)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-NIVO-AVD |
| ID | IND-CHL-1L-N-AVD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L emerging standard for advanced cHL. Likely to displace A+AVD where access feasible. Off-label for cHL in UA — funding pathway via institutional appeal.
Used By
No reverse references found in the YAML corpus.